Posted 06 August, 2021
Adagio Therapeutics, Inc. IPO completed
IPO completed detected for ticker Nasdaq:IVVD in a 424B4 filed on 06 August, 2021.
This is our initial public offering and no public market exists for our common stock.
Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Adagio Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.Market Cap
$437M
View Company Details
$437M
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.